ライフサイエンスコーパス: bivalent

1 able loss in k-fibres, or tension across the bivalent.

2 mic details of the binding mode of mono- and bivalent 14-3-3 interactions.

3 tion was enriched at CpG islands marked with bivalent activating and repressing histone modifications

4 P gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 hist

5 components (TOG and RNA) are modulated by a bivalent adaptor molecule (hnRNP A2).

6 bsAEC showed a higher affinity than that of bivalent AEC with two identical anti-EGFR scFvs at low c

7 loaddition using bis(TMS)butadiyne and other bivalent alkynes.

8 h end of the tetramer, which would allow one bivalent ALYREF protein to bridge adjacent helicases and

9 The interference caused by bivalent and monovalent OPV formulations, which will be

10 Bivalent and quadrivalent HPV vaccines protect against 6

11 Bivalent and quadrivalent HPV vaccines were licensed in

12 First generation bivalent and quadrivalent human papillomavirus (HPV) vac

13 shown to be cost-effective compared with the bivalent and quadrivalent vaccines at any coverage despi

14 exchange of chromatin fibers between paired bivalents and asynapsed chromosomes.

15 A panel of 16 bivalent anti-HER2 antibodies were prepared wherein each

16 antibodies has been challenging, however, as bivalent antibodies exhibit agonistic properties, wherea

17 ach enables the generation of monovalent and bivalent antibodies with nanomolar affinity for Abeta fi

18 Importantly, like monovalent pMHC and unlike bivalent antibodies, monovalent Fab'-DNA triggers TCRs o

19 tween rod-like virus particles (virions) and bivalent antibodies.

20 saturating antibody concentrations, and that bivalent antibody binding may be more common than previo

21 Bivalent antireceptor antibodies can elicit insulin-like

22 Such a bivalent approach may provide a mechanism for fine tunin

23 is study, a signal-on nanobiosensor based on bivalent aptamer-Cu nanocluster was designed and optimiz

24 Our results support that the bivalent aptamer-driven delivery of two siRNAs could be

25 ent work reports the engineering of circular bivalent aptamer-drug conjugates (cb-ApDCs).

26 otic defects including improper alignment of bivalents at metaphase I, unequal chromosome segregation

27 The method developed outperforms existing bivalent-based methods, which may fail to model and anal

28 as been made, the homologues of a 4-mum-long bivalent begin to separate.

29 Bivalent (BG505 and B41) trimer IO-NPs were made, as wer

30 eries showed enhanced potency as a result of bivalent binding and a clear correlation between BRD4 ac

31 e 53BP1-dependent repair through competitive bivalent binding and modification of chromatin.

32 array data may be explained by the possible bivalent binding mode of a single human-specific HA trim

33 RIPLET uses its dimeric structure and a bivalent binding mode to preferentially recognize and ub

34 e plasmon resonance measurements supported a bivalent binding model in which multiple sites on PAI-1

35 co-localization of reactants induced by the bivalent binding of a specific IgG antibody to two antig

36 Fab domain flexibility necessary for hetero-bivalent binding to the Env trimer while retaining the f

37 ectively, our successful application of the "bivalent bioisostere concept" identified a promising lea

38 ed analogue INTA by adopting the concept of "bivalent bioisostere".

39 lecular modeling studies revealed that these bivalent bioisosteres may adopt similar binding modes in

40 lored the possibility of using antibodies as bivalent biomolecular substrates for the templated assem

41 However, bivalent biorientation remained uncoupled from APC activ

42 We show that a bivalent biparatopic antibody targeting two non-overlapp

43 onovalent bispecific variants, but not their bivalent bispecific counterparts, mediated a greater deg

44 Specifically, a series of monovalent and bivalent bispecific IgGs composed of the anti-HER2 trast

45 e April 2016 switch from trivalent (tOPV) to bivalent (bOPV) oral polio vaccine at the national-level

46 we report the DNA-mediated self-assembly of bivalent bottlebrush polymers, a process akin to the ste

47 he discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors.

48 ity in older US adults of an investigational bivalent C. difficile vaccine that contains equal dosage

49 iently as a reference mouse mAb and that the bivalent CA4910 nanobody behaves as an efficient antagon

50 Engineering of a bivalent CA4910 nanobody resulted in a relatively modest

51 that the conjunction of hypermethylation of bivalent chromatin and up-regulation of the correspondin

52 Bivalent chromatin at MHC-I APP genes is a normal develo

53 the polycomb repressive complex 2 to induce bivalent chromatin at the Wapl promoter.

54 Experimental evidence indicates that bivalent chromatin domains, i.e., genome regions that ar

55 KSHV episomes are known to possess bivalent chromatin domains.

56 n shown to exhibit partial recapitulation of bivalent chromatin modifications that are lost along wit

57 rmal colonocyte differentiation, exists in a bivalent chromatin state.

58 ndidate genes are significantly enriched for bivalent chromatin structure, suggesting this configurat

59 lation across domains marked by H3K27me3 and bivalent chromatin, and de-repression of developmental r

60 ver, Plk1 cKO oocytes failed to form compact bivalent chromosomes, and localization of cohesin and co

61 hylates H3K4 on many developmental genes and bivalent clusters.

62 8, Smc1beta is not required for establishing bivalent cohesion [11, 12].

63 o Smc3/Smc1alpha or Smc3/Smc1beta, maintains bivalent cohesion in mammalian meiosis [2-6].

64 e propose that identification of PRC1-Br140 "bivalent complexes" in fly embryos supports and extends

65 gradation of non-native neo-substrates using bivalent compounds known as PROTACs (for 'proteolysis-ta

66 and/or N-5 of 1 and the capacity of the new bivalent compounds to selectively activate G-proteins ve

67 The stability of the bivalent configuration against the monovalent one is con

68 loid-like behaviour at metaphase I involving bivalent configurations was predominant in all three tet

69 Addition of bivalent D2 receptor ligands also resulted in a large in

70 A bivalent decoy, CTC-445.2d, showed ~10-fold improvement

71 study cholesteric shells with monovalent and bivalent defect configurations.

72 work for structure-activity relationships of bivalent degraders are anticipated to have wide future a

73 methylome, with gradual hypermethylation of bivalent developmental genes.

74 ential gene expression - specifically at the bivalent developmental genes.

75 nteractions of the Influenza A virus HA with bivalent displays of the natural sialyl-LacNAc ligand.

76 nt monomers, Fab HC84.26.5D assembles into a bivalent domain-swapped dimer in which the two V(L)/V(H)

77 Bivalent domain-swapped Fab dimers engineered on the bas

78 lysis reveals that these de novo synthesized bivalent domains are largely associated with a subset of

79 lishment and maintenance of H3K4me3/H3K27me3 bivalent domains underlying methylated DNA CpG islands (

80 recruitment and activity of DNMT3A(D329A) at bivalent domains.

81 frequently co-occupy gene promoters, forming bivalent domains.

82 et-driven combinatorial chemistry to deliver bivalent drugs in a small molecule form.

83 l for the formation of segregation-competent bivalents during meiosis I, and findings suggest that ag

84 These results demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and ce

85 Immunization of rabbits with bivalent Ebola VLPs produced antibodies that neutralized

86 n 80 angstrom linker had the most pronounced bivalent effects, with a significantly slower dissociati

87 ions were synthesized by the reaction of the bivalent electrophile thiabicyclo[3.3.1]nonane dinitrate

88 ggering off-target T-cell activation through bivalent engagement and dimerization of T-cell receptors

89 and were selectively enriched for poised and bivalent enhancer marks.

90 27me3-associated inactive states and poised (bivalent) enhancer states.

91 This bivalent epigenetic control of oncofetal gene expression

92 re maintained in a stem-like state through a bivalent epigenetic mechanism.

93 We examined the poised (H3K4me3/H3K27me3 bivalent) epigenetic state in male germ cells from five

94 main pure antagonists even when formatted as bivalent Fc-fusion proteins, making this an attractive t

95 of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum.

96 DPPA2/4 bind both H3K4me3-marked and bivalent gene promoters and associate with COMPASS- and

97 eradicates PRC2 targeting on the majority of bivalent gene promoters and leads to transcriptional de-

98 omb within minutes, leading to activation of bivalent gene transcription in mouse embryonic stem cell

99 not Mll2 functions as the H3K4 methylase on bivalent genes and is required for their expression, sup

100 ion of numerous retinoic acid (RA)-inducible bivalent genes during the RA-driven differentiation of m

101 to other studied systems, SMARCB1 represses bivalent genes in hESCs and antagonizes chromatin access

102 genes and is causally implicated in keeping bivalent genes silent.

103 We identify a dichotomy between bivalent genes that do and do not become hypermethylated

104 tion to implementing H3K4me3 at promoters of bivalent genes, Mll2 (KMT2B)/COMPASS can also implement

105 /4 results in rapid loss of H3K4me3 from key bivalent genes, while H3K27me3 is initially more stable

106 methylation of iCCA, affecting primarily the bivalent genomic regions marked with both active and rep

107 accinations and coadministration of purified bivalent gp120 proteins (AIDSVAX B/E).

108 llar vesicles in water (CAC < 0.25 muM), and bivalent guests 4/5 populating the cavities of such bola

109 how that KMT2B is essential for establishing bivalent H3K4me3 at E6.5 but becomes partially dispensab

110 n cold-stored tubers are associated with the bivalent H3K4me3-H3K27me3 mark in gene body regions.

111 hypothesize that in cold-stored tubers, the bivalent H3K4me3-H3K27me3 mark represents a distinct chr

112 y histone H3K4me1, histone H3K27me3, and the bivalent histone mark H3K27me3 + H3K4me3 in human CD34+

113 found that ZIC2 degradation by K-Rta shifts bivalent histone marks to a more active configuration, l

114 Bivalent histone modifications are defined as repressive

115 tently, Tol2 insertions were associated with bivalent histone modifications characteristic of silent

116 induces enhanced chromatin accessibility and bivalent histone modifications of active genes.

117 ly, depletion of ZIC2 shifted the balance of bivalent histone modifications toward more active forms

118 ate that developmental gene loci, which have bivalent histone modifications, tend to colocalize in PS

119 e in embryonic stem cells but premarked with bivalent histone modifications; one allele was silenced

120 The BAH-PHD bivalent histone reader complex silences a substantial s

121 X-mediated resolution and activation of many bivalent Hox genes during mouse ESC differentiation were

122 Bivalent HPV vaccination of 12-year-old girls resulted i

123 efore and 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline).

124 the immunogenicity of a booster dose of both bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine

125 ith the aim of assessing the efficacy of the bivalent HPV vaccine for preventing HPV 16/18-associated

126 The bivalent HPV vaccine has high efficacy against HPV 16/18

127 s) or 3 doses (at 0, 1, and 6 months) of the bivalent HPV vaccine were identified in the vaccination

128 r to explain partial cross-protection by the bivalent HPV vaccine.

129 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in me

130 alizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion.

131 s-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) stud

132 The bivalent human papillomavirus (HPV) vaccine is highly ef

133 or routine vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine.

134 Our results suggest a model where the bivalent IgG acts akin to molecular pliers, pulling the

135 shows essentially no inhibition, whereas the bivalent IgG fully inhibits beta-tryptase activity in a

136 gaging HER2 and IL13Ralpha2 in an augmented, bivalent immune synapse that enhances T cell functionali

137 d on a cyclic defensin protein, as well as a bivalent immunogen with two copies of the epitope on the

138 one and not many more than one crossover per bivalent in most taxa.

139 tective efficacy of FILORAB1, a recombinant, bivalent, inactivated rabies virus-based EBOV vaccine, i

140 We found that PRC2 binds to a bivalent inhibitor unit consisting of an H3K27M and an H

141 optimized setting for the rational design of bivalent inhibitors that bridge two adjacent sites.

142 Bivalent inhibitors, where two pharmacophores are tether

143 inding affinities to introduce dependence on bivalent interaction, i.e. avidity.

144 Sorting of LPL requires bivalent interactions between LPL and SDC1-linked hepara

145 The 111-residue RAM region mediates bivalent interactions of NICD with the transcription fac

146 ecruited to DNA double-strand breaks through bivalent interactions with both histone and DNA componen

147 gomerization and tandem-BRCT domain-mediated bivalent interactions with p53 and the ubiquitin-specifi

148 We propose that bivalent interactions with the double stranded RNA bindi

149 A bivalent intranasal RSV/HPIV3 vaccine candidate consisti

150 ne units through a rigid pyrrole spacer, the bivalent ligand norbinaltorphimine was formed.

151 ments demonstrate that FGF23-WT can act as a bivalent ligand of KLA in the cell membrane.

152 84, the prototype of our previously reported bivalent ligand TTR 'superstabiliser' family, is notably

153 , this is the first report of a melanocortin bivalent ligand's in vivo physiological effects.

154 In contrast, mds84, our prototypic "bivalent" ligand, which is a more potent stabilizer of T

155 We present unmatched bivalent ligands (UmBLs) to study the asymmetric functio

156 A functional switch is observed for the bivalent ligands 3b,c inhibiting cAMP formation in cells

157 We report here bivalent ligands consisting of two identical oxytocin-mi

158 The development of bivalent ligands has attracted interest as a way to pote

159 d mGlu(2) ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-H

160 The bivalent ligands show binding affinity in the picomolar

161 ent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-TM

162 study focused on the design and synthesis of bivalent ligands to target melanocortin receptor homodim

163 roviding evidence of the discrete effects of bivalent ligands.

164 ssociated RNA sequencing)), which also use a bivalent linker to ligate RNA and DNA in proximity.

165 ntation, RNA and DNA in situ ligation with a bivalent linker, PCR amplification and high-throughput s

166 ncRNAs classes such as enhancer-RNAs (eRNA), bivalent-lncRNAs, and CTCF-associated, among others.

167 pancy of PRC1 and a Br140 ortholog, BRD1, at bivalent loci in human embryonic stem (ES) cells.

168 c polypeptide was also accomplished to yield bivalent M6P-glycopeptides.

169 Bivalent mAb-TM was superior to monovalent scFv-TM in bo

170 e-specifically radiolabeled mono- (scFv) and bivalent (mAb) affinity ligands specific for the endothe

171 would be unable to bind the CD73 dimer in a bivalent manner, implicating crosslinking of separate CD

172 sponse, whereas downregulated genes with the bivalent mark are involved in developmental processes.

173 ingly, upregulated genes associated with the bivalent mark are involved in stress response, whereas d

174 We focus on the abundant bivalent mark H3K27me3K36me2, showing that H3K27me3 domi

175 NA PolII, H3K27ac, and H3K36me3, but not the bivalent mark H3K4me2.

176 In addition, we observe that the bivalent mark-associated genes are more accessible than

177 Groups of tissue-specific genes that carry bivalent marks are repressed, despite the presence of pr

178 n knockout, most of these promoters gain the bivalent marks, H3K4me3 and H3K27me3.

179 oncomitant depletion of H3K27me3 and H3K4me3 bivalent marks.

180 ovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous

181 These bivalent modifications are maintained at most somatic pr

182 to most global HIV-1 variants and employs a bivalent mosaic design, it is expected that it could be

183 We recently developed novel bivalent mosaic T-cell vaccine immunogens composed of co

184 length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, 18a a

185 We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine can

186 une responses in a phase 2 trial of Takeda's bivalent norovirus virus-like particle (VLP) vaccine can

187 We identified definitively bivalent nucleosomes with concomitant repressive and act

188 s to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalen

189 hronized switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) as recommended by the Strategic Advi

190 e global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) can inform the eventual full global

191 bal replacement of trivalent OPV (tOPV) with bivalent OPV (bOPV) during April - May 2016, a transitio

192 and to "switch" from trivalent OPV (tOPV) to bivalent OPV (bOPV) in all countries still using OPV in

193 containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 and 3 poliovirus)

194 PV (tOPV; types 1, 2, and 3 polioviruses) to bivalent OPV (bOPV; types 1 and 3 polioviruses) during a

195 (containing types 1, 2, and 3 poliovirus) to bivalent OPV (containing types 1 and 3 poliovirus) calle

196 vaccine in any of the 5 campaigns delivering bivalent OPV (serotypes 1 and 3) conducted during Septem

197 as poliovirus shedding in stool 7 days after bivalent OPV challenge at 11 months.

198 oconversion was increased with monovalent or bivalent OPV compared with trivalent OPV (RR 1.51, 95% C

199 settlements and 92% in Nayapara received >3 bivalent OPV doses in campaigns.

200 or use of inactivated poliovirus vaccine and bivalent OPV in routine immunization.

201 n of one or two full doses of an IPV after a bivalent OPV schedule increased the RR to 0.85 (0.75-1.0

202 However, the addition of an IPV to bivalent OPV schedules did not significantly increase in

203 receive 3 doses of monovalent OPV type 1 or bivalent OPV types 1 and 3 at either 6, 8, and 10 or 6,

204 d between inactivated poliovirus vaccine and bivalent OPV.

205 (RR) of seroconversion after three doses of bivalent OPVs was 0.14 (95% CrI 0.11-0.17) compared with

206 l 2016, with a switch from trivalent OPVs to bivalent OPVs.

207 The genesis of designing bivalent or bitopic molecules that engender unique pharm

208 d, we develop a fitting-free, minimal model: bivalent or multivalent red and green 'transcription fac

209 e estimated the lifetime health benefits for bivalent or quadrivalent and nonavalent vaccination of 9

210 erted per 1000 vaccinated girls for both the bivalent or quadrivalent and nonavalent vaccines, compar

211 With the updated model, the bivalent or quadrivalent HPV vaccine was estimated to av

212 rotein containing VLPs either as monovalent, bivalent or tetravalent formulation resulted in generati

213 Coadministration of monovalent, bivalent, or trivalent OPV seems to lower RV1 immunogeni

214 replacing trivalent oral polio vaccine with bivalent oral polio vaccine ("the switch").

215 from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) ("the switch") presen

216 from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) has constituted an ef

217 in relation to the switch from trivalent to bivalent oral polio vaccine (OPV) in the 11 countries of

218 (Ty21a) by using it as a vector to develop a bivalent oral vaccine to protect against S. sonnei shige

219 Focusing on the bivalent PAX6 locus, we find that increased DNMT3B bindi

220 enetic approach, we demonstrate utility of a bivalent pharmacophore with dual activity as a mu/delta

221 nalogue, we have developed a set of uni- and bivalent photoswitchable toolbox derivatives of the high

222 Bivalent (poised or paused) chromatin comprises activati

223 viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulations should be tested i

224 bryonic stem cells (hESCs) exhibit prominent bivalent promoter hypermethylation without an overall co

225 late known patterns such as super-enhancers, bivalent promoters and Polycomb repressed regions, and i

226 ape at a subset of developmentally important bivalent promoters characterized by low expression and p

227 elf-renewing tissues show fewer and distinct bivalent promoters compared to ESCs.

228 ses, we conclude that TET proteins safeguard bivalent promoters from de novo methylation to ensure ro

229 Bivalent promoters in embryonic stem cells (ESCs) carry

230 cape and for maintaining the fidelity of the bivalent promoters in hESCs.

231 Typically, DNA at bivalent promoters is only lowly methylated in normal ce

232 induction, Ezh2 loss derepresses a subset of bivalent promoters that resolve toward gene activation,

233 Gene ontology analysis associated spurious bivalent promoters with development and cell differentia

234 IRF6 was enriched at bivalent promoters, and IRF6 deficiency caused defective

235 loss released the poised state of apparently bivalent promoters, whereas downregulated genes were enr

236 We call them spurious bivalent promoters.

237 pposition of Polycomb-mediated repression at bivalent promoters.

238 expressing RSV fusion (F) protein to confer bivalent protection against RSV and HPIV3.

239 ay play a critical role in the resolution of bivalent protein complexes during development.

240 The activated ProINS-Tf, serving as a bivalent protein molecule, could be a new insulin analog

241 rs against rabies virus, illustrating that a bivalent rabies virus-based vaccine against CDV induces

242 se data are consistent with a model in which bivalent recruitment of a GADS/SLP-76 complex is require

243 lterations affect mainly heterochromatic and bivalent regions and provide possible explanations for t

244 Furthermore, our findings also show that bivalent regions have fewer nucleosome-depleted regions

245 We find that loss of H3K4me3 at bivalent regions is associated with gain of methylation.

246 ents who had received three doses of 120 mug bivalent rLP2086 (the optimum dose level identified in s

247 11, 170 participants who received 120 mug of bivalent rLP2086 and 80 participants who received placeb

248 ted in seven (4%) of 170 participants in the bivalent rLP2086 group and two (3%) of 80 participants i

249 Bivalent rLP2086 is a recombinant factor H binding prote

250 trains (A22, A56, and B24), more than 50% of bivalent rLP2086 recipients continued to achieve titres

251 INTERPRETATION: After three doses of bivalent rLP2086, protective hSBA titres above the corre

252 After three doses of bivalent rLP2086, protective hSBA titres above the corre

253 up to 4 years after a three-dose schedule of bivalent rLP2086.

254 we describe the preclinical development of a bivalent RSV/HPIV1 vaccine based on a recombinant HPIV1

255 imeric rB/HPIV3 vector expressing RSV F as a bivalent RSV/HPIV3 vaccine and have been evaluating mean

256 nificantly increased F immunogenicity in the bivalent RSV/HPIV3 vaccine.

257 The bivalent scaffolds presented two sialyl-LacNAc ligands i

258 Switching from a monovalent scFv to a bivalent scFv-Fc format improved its binding affinity to

259 The scFv-CD44 was reformatted into a bivalent scFv-Fc-CD44, based on human IgG(1)-fragment cr

260 volume on the ability of the SAC to inhibit bivalent segregation in meiosis I.

261 In this work, we study a bivalent, sequential-step binding scheme as an alternati

262 Bivalent shells possess two highly structured defects, w

263 By virtue of a new bivalent side chain on bPNA+, similar DNA affinity and h

264 f a complex formed by a SUMO3 dimer with the bivalent SIM2-SIM3 peptide.

265 2019;141:2960-2974) reported a bivalent small molecule inhibitor of primary miRNA (pri-

266 Here, we report the development of a bivalent, spherical Ebola virus-like particle (VLP) vacc

267 Disruption of the bivalent state through inhibition of the H3K27 methyltra

268 pecific differentiation genes are found in a bivalent state, having both activating H3K4me3 and repre

269 d in either inhibition of transcription or a bivalent status of the genes.

270 tigen of V. cholerae We demonstrate that the bivalent structure of IgG, although not required for bin

271 V (vCP2438) alone at months 0 and 1 and with bivalent subtype C gp120/MF59 at months 3, 6, and 12.

272 Our group developed a family of bivalent synbody affinity ligands using a virus-like par

273 To maximize bivalent target engagement, we synthesized an oriented,

274 This revealed a circuit of bivalent TFAP2A, TFAP2C, GATA2, and GATA3 transcription

275 Thus, TRB1 is a bivalent transcriptional modulator that maintains downre

276 trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated p

277 was replaced worldwide from April, 2016, by bivalent types 1 and 3 oral polio vaccine (bOPV) and one

278 rivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) an

279 A bivalent typhoid and paratyphoid vaccine is needed.

280 Bivalent V(H), V(H)-Fc ab8, bound with high avidity to m

281 INTERPRETATION: Bivalent vaccination has led to a startling reduction in

282 rB/HPIV3 expressing wt RSV G provides a bivalent vaccine against RSV and HPIV3.

283 &G recombinant virus is a safe and effective bivalent vaccine candidate and that the expression of bo

284 in (G) genes of AMPV subtype-C (AMPV-C) as a bivalent vaccine candidate using reverse genetics techno

285 In this study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine

286 D. nodosus in England to elucidate whether a bivalent vaccine could protect the national flock.

287 , 2005, designed to assess the efficacy of a bivalent vaccine for the prevention of infection with HP

288 y, we report on vaccine effectiveness of the bivalent vaccine in these vaccinated women who attended

289 Consequently, a bivalent vaccine targeting these two serogroups would pr

290 We conclude that one bivalent vaccine would not protect the national flock ag

291 >=1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are assoc

292 We constructed novel bivalent vaccines through the recombinant expression of

293 e serogroups, has low efficacy compared with bivalent vaccines.

294 ab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, i

295 linically in mice, for the delivery of novel bivalent viral-vectored vaccines.

296 onth after intramuscular administration of 2 bivalent virus-like particle (VLP)-based candidate norov

297 Vaccination of rhesus macaques with bivalent VLPs generated strong humoral immune responses,

298 The crossover frequency per bivalent was significantly reduced in the tetraploids co

299 is, localization of topoisomerase IIalpha to bivalents was not affected; however, localization of con

300 Nevertheless, bivalents were accompanied by a substantial frequency of